Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.